Metastatic Hepatocellular Carcinoma (HCC) Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 43 pages | ID: M044D4F2A07EN
VPAResearch

Abstracts

Metastatic Hepatocellular Carcinoma (HCC) ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Metastatic Hepatocellular Carcinoma (HCC) disease clinical trials. The research work analyzes the ongoing Metastatic Hepatocellular Carcinoma (HCC) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Metastatic Hepatocellular Carcinoma (HCC) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Metastatic Hepatocellular Carcinoma (HCC) clinical trials.

Scope of the Report-

• Ongoing Metastatic Hepatocellular Carcinoma (HCC) clinical trials across regions
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Metastatic Hepatocellular Carcinoma (HCC)
• Both observational and interventional trials analyzed
• Leading companies and universities participating in Metastatic Hepatocellular Carcinoma (HCC) clinical trials

Reasons to Buy

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Metastatic Hepatocellular Carcinoma (HCC) Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials by Phase
3.2 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials by Type
3.3 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials
4.2 Top 10 Countries conducting Metastatic Hepatocellular Carcinoma (HCC) Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials by Sponsor Type
5.2 Metastatic Hepatocellular Carcinoma (HCC) Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Metastatic Hepatocellular Carcinoma (HCC) Trials by year
6.2 Subjects Recruited for Metastatic Hepatocellular Carcinoma (HCC) Trials by Phase
6.3 Subjects Recruited for Metastatic Hepatocellular Carcinoma (HCC) Trials by Trial Type
6.4 Subjects Recruited for Metastatic Hepatocellular Carcinoma (HCC) Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials- Phase
7.2 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials- Phase
7.3 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials- Phase
7.4 Ongoing Metastatic Hepatocellular Carcinoma (HCC) Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Country
Figure 2: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Phase of Development, 2018
Figure 3: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Status, 2018
Figure 4: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Type, 2018
Figure 5: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials Split by Region, 2000-2018
Figure 6: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Type of Economy, 2018
Figure 7: Metastatic Hepatocellular Carcinoma (HCC)- Enrolment by Phase, 2018
Figure 8: Metastatic Hepatocellular Carcinoma (HCC)- Enrolment by Trial Type, 2018
Figure 9: Metastatic Hepatocellular Carcinoma (HCC)- Enrolment by Recruitment Status, 2018
Figure 10: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Sponsor Type, 2018
Figure 11: Metastatic Hepatocellular Carcinoma (HCC)- Enrolment by Type of Sponsors
Figure 12: Metastatic Hepatocellular Carcinoma (HCC)- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Sponsor Type, 2018
Table 2: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Economy Type, 2018
Table 3: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials by Region, 2018
Table 4: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Metastatic Hepatocellular Carcinoma (HCC)- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Metastatic Hepatocellular Carcinoma (HCC)- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Metastatic Hepatocellular Carcinoma (HCC)- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Metastatic Hepatocellular Carcinoma (HCC)- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Metastatic Hepatocellular Carcinoma (HCC)- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company